Welcome to our dedicated page for Incannex Healthcare news (Ticker: ixhl), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Ltd (IXHL) is a clinical-stage biopharmaceutical innovator developing novel cannabinoid and psychedelic-assisted therapies for chronic medical conditions. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's research advancements and operational milestones.
Access authoritative information about IXHL's clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes press releases on sleep apnea therapies, inflammatory disease treatments, and neurological disorder research – all critical to understanding the company's progress in psychedelic medicine and cannabinoid science.
Key updates cover therapeutic program developments, Australian medicinal cannabis license utilization, and financial strategy implementations. Stay informed about IXHL's pioneering work through verified announcements regarding clinical-stage breakthroughs and research collaborations.
Bookmark this page for direct access to Incannex Healthcare's official communications. Regularly updated content ensures you maintain current awareness of their innovative approaches to addressing unmet medical needs through advanced pharmaceutical research.
MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) has appointed Quest Pharmaceutical Services (‘QPS’) to provide regulatory advice and manage clinical trials for its CannQuit™ and ReneCann™ products aimed at addressing addiction and immune-related skin disorders. QPS will handle pre-investigational new drug submissions for both the European Medicines Agency and the US Food and Drug Administration. The CannQuit™ line includes two controlled-release chewing gums combining CBD with nicotine and opioid treatments, while ReneCann™ targets conditions like psoriasis and eczema using a proprietary cannabinoid formulation. These products were acquired from APIRx Pharmaceuticals and are being developed in collaboration with Eurofins Scientific. The global markets for these treatments represent significant economic opportunities for Incannex.
Incannex Healthcare Ltd (NASDAQ: IXHL) is advancing plans to launch multiple psychedelic-assisted psychotherapy clinics in Australia and globally. The first clinic in Melbourne is set to open in 2023 with expectations for rapid expansion. Key board appointments include Dr. Paul Liknaitzky and Professor Suresh Sundram, enhancing clinical expertise. The company views the evolving psychedelic therapy market as a potential multi-billion-dollar opportunity. Ongoing negotiations for premises are at an advanced stage, demonstrating Incannex's commitment to expanding its service delivery beyond research.
Incannex Healthcare (NASDAQ: IXHL) announced positive interim results from its Phase 2 trial of psilocybin-assisted psychotherapy for Generalised Anxiety Disorder (GAD), named "PsiGAD." An analysis of data from 29 participants shows over an 85% likelihood of significant benefits compared to placebo. An independent Data Safety Monitoring Board found no safety concerns and recommended no changes to the study's design. The trial, which involves 72 participants, is proceeding on schedule, with full completion expected in Q4 2023. CEO Joel Latham emphasized confidence in the treatment's potential to transform anxiety care.
Incannex Healthcare Limited (Nasdaq: IXHL) has partnered with Catalent for the development and cGMP manufacture of its psilocybin drug product. This initiative supports Incannex's PsiGAD clinical development program targeting generalized anxiety disorder. The drug product aims for future regulatory filings, including IND applications. Internal analysis of interim data from the PsiGAD phase 2 clinical trial has allowed the company to confidently proceed. CEO Joel Latham emphasized that having access to pharmaceutical-grade psilocybin opens clinical trial potential and commercial opportunities, with updates expected soon.
